Optimal haemophilia care versus the reality

British Journal of Haematology

Volumn 132, Issue 6, 2006, Pages 671-682

  Bolton Maggs, Paula H B ^a  

^a MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Factor concentrates; Haemophilia A and B; Hepatitis C; HIV; Inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; DESMOPRESSIN; PEGINTERFERON; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RIBAVIRIN;

ANAPHYLAXIS; ARTHROPATHY; BLEEDING; BLOOD TRANSFUSION; CLINICAL TRIAL; DEPRESSION; DRUG MEGADOSE; GENE MUTATION; GENETIC COUNSELING; HEALTH CARE COST; HEALTH CENTER; HEALTH SERVICE; HEMOPHILIA A; HEMOPHILIA B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MOOD DISORDER; MORBIDITY; NEPHROTIC SYNDROME; NONHUMAN; PATIENT CARE; PHYSIOTHERAPY; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; REVIEW; X CHROMOSOME LINKED DISORDER;

ADOLESCENT; ADULT; BLOOD COAGULATION FACTORS; CHILD; COMPREHENSIVE HEALTH CARE; COST-BENEFIT ANALYSIS; FINANCING, ORGANIZED; HEMOPHILIA A; HEMOPHILIA B; HEPATITIS C; HIV INFECTIONS; HUMANS; PATIENT CARE TEAM; QUALITY OF HEALTH CARE; SEPSIS;

EID: 33644977557     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2005.05952.x     Document Type: Review

References (137)

1. Aronstam A. Wasssef M. Choudhury D.P. Turk P.M. McLellan D.S. 1980 Double-blind controlled trial of three dosage regimens in treatment of haemarthroses in haemophilia A Lancet 1 169 171
2. Aronstam A. Wassef M. Hamad Z. Cartlidge J. McLellan D. 1983 A double-blind controlled trial of two dose levels of factor VIII in the treatment of high risk haemarthroses in haemophilia A Clinical and Laboratory Haematology 5 157 163
3. Arruda V.R. Schuettrumpf J. Herzog R.W. Nichols T.C. Robinson N. Lotfi Y. Mingozzi F. Xiao W. Couto L.B. High K.A. 2004 Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1 Blood 103 85 92
4. Arruda V.R. Stedman H.H. Nichols T.C. Haskins M.E. Nicholson M. Herzog R.W. Couto L.B. High K.A. 2005 Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model Blood 105 3458 3464
5. Astermark J. Petrini P. Tengborn L. Schulman S. Ljung R. Berntorp E. 1999 Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized British Journal of Haematology 105 1109 1113
6. Astermark J. Berntorp E. White G.C. Kroner B.L. 2001 The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients Haemophilia 7 267 272
7. Avidan M.S. Levy J.H. van Aken H. Feneck R.O. Latimer R.D. Ott E. Martin E. Birnbaum D.E. Bonfiglio L.J. Kajdasz D.K. Despotis G.J. 2005 Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass Journal of Thoracic and Cardiovascular Surgery 130 107 113
8. Baru M. Carmel-Goren L. Barenholz Y. Dayan I. Ostropolets S. Slepoy I. Gvirtzer N. Fukson V. Spira J. 2005 Factor VIII efficient and specific non-covalent binding to PEGylated liposomes enables prolongation of its circulation time and haemostatic efficacy Thrombosis and Haemostasis 93 1061 1068
9. Beeton K. Tuffley J. 2005 Physiotherapy in the management of hemophilia In: Textbook of Hemophilia ed. by Lee C. Berntorp E. Hoots K. pp 193 199 Blackwell Oxford
10. Beeton K. Cornwell J. Alltree J. 1998 Muscle rehabilitation in haemophilia Haemophilia 4 532 537
11. Beltran-Miranda C.P. Khan A. Jaloma-Cruz A.R. Laffan M.A. 2005 Thrombin generation and phenotypic correlation in haemophilia A Haemophilia 11 326 334
12. Benhamou Y. Hinrichsen H. Sentjens R. Reiser M. Manns M.P. Forns X. Avendano C. Cronlein J. Nehmiz G. Steinmann G. 2002 Safety, tolerability, and antiviral effects of BILN2061, a novel HCV serine protease inhibitor, after oral treatment over 2 days in patients with chronic hepatitis C, genotype 1, with advanced liver fibrosis Hepatology 304A 563
13. Berntorp E. 2003 Prophylactic therapy for haemophilia: early experience Haemophilia 9 Suppl. 1 5 9 discussion 9
14. Berntorp E. Boulyjenkov V. Brettler D. Chandy M. Jones P. Lee C. Lusher J. Mannucci P. Peake I. Rickard K. Seremetis S. 1995 Modern treatment of haemophilia Bulletin of the World Health Organization 73 691 701
15. Berntorp E. Astermark J. Bjorkman S. Blanchette V.S. Fischer K. Giangrande P.L. Gringeri A. Ljung R.C. Manco-Johnson M.J. Morfini M. Kilcoyne R.F. Petrini P. Rodriguez-Merchan E.C. Schramm W. Shapiro A. van den Berg H.M. Hart C. 2003 Consensus perspectives on prophylactic therapy for haemophilia: summary statement Haemophilia 9 Suppl. 1 1 4
16. Blanchette V.S. McCready M. Achonu C. Abdolell M. Rivard G. Manco-Johnson M.J. 2003 A survey of factor prophylaxis in boys with haemophilia followed in North American haemophilia treatment centres Haemophilia 9 Suppl. 1 19 26 discussion 26
17. Blanchette V.S. Manco-Johnson M. Santagostino E. Ljung R. 2004 Optimizing factor prophylaxis for the haemophilia population: where do we stand Haemophilia 10 Suppl. 4 97 104
18. Bollard C.M. Teague L.R. Berry E.W. Ockelford P.A. 2000 The use of central venous catheters (portacaths) in children with haemophilia Haemophilia 6 66 70
19. Bolton-Maggs P.H. Stobart K. Smyth R.L. 2004 Evidence-based treatment of haemophilia Haemophilia 10 Suppl. 4 20 24
20. van der Bom J.G. Mauser-Bunschoten E.P. Fischer K. van den Berg H.M. 2003 Age at first treatment and immune tolerance to factor VIII in severe hemophilia Thrombosis and Haemostasis 89 475 479
21. Bray G.L. Gomperts E.D. Courter S. Gruppo R. Gordon E.M. Manco-Johnson M. Shapiro A. Scheibel E. White III. G. Lee M. 1994 A multicenter study of recombinant factor VIII (recombinate): safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A. The Recombinate Study Group Blood 83 2428 2435
22. Brown B.D. Shi C.X. Powell S. Hurlbut D. Graham F.L. Lillicrap D. 2004 Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A Blood 103 804 810
23. Buckley R.H. 2002 Gene therapy for SCID - a complication after remarkable progress Lancet 360 1185 1186
24. Bullinger M. von Mackensen S. 2004 Quality of life assessment in haemophilia Haemophilia 10 Suppl. 1 9 16
25. Carmen I.H. 2001 A death in the laboratory: the politics of the Gelsinger aftermath Molecular Therapy 3 425 428
26. Chalmers E.A. Williams M.D. Richards M. Brown S.A. Liesner R. Thomas A. Vidler V. Pasi K.J. Hill F.G. 2005 Management of neonates with inherited bleeding disorders - a survey of current UK practice Haemophilia 11 186 187
27. Chambost H. Ljung R. 2005 Changing pattern of care of boys with haemophilia in western European centres Haemophilia 11 92 99
28. Chuah M.K. Collen D. Vandendriessche T. 2004 Preclinical and clinical gene therapy for haemophilia Haemophilia 10 Suppl. 4 119 125
29. Connelly S. Andrews J.L. Gallo-Penn A.M. Tagliavacca L. Kaufman R.J. Kaleko M. 1999 Evaluation of an adenoviral vector encoding full-length human factor VIII in hemophiliac mice Thrombosis and Haemostasis 81 234 239
30. Darby S.C. Ewart D.W. Giangrande P.L. Spooner R.J. Rizza C.R. Dusheiko G.M. Lee C.A. Ludlam C.A. Preston F.E. 1997 Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation Lancet 350 1425 1431
31. Darby S.C. Kan S.W. Spooner R.J. Giangrande P.L. Lee C.A. Makris M. Sabin C.A. Watson H.G. Wilde J.T. Winter M. 2004 The impact of HIV on mortality rates in the complete UK haemophilia population AIDS 18 525 533
32. Department of Health 1976 Organisation of Haemophilia Centres Health Circular. HC(76) 4 HMSO London
33. Department of Health 1993 Provision of Haemophilia Treatment and Care Health Circular. HSG (93) 30 HMSO London
34. van Dijk K. van der Bom J.G. Lenting P.J. de Groot P.G. Mauser-Bunschoten E.P. Roosendaal G. Grobbee D.E. van den Berg H.M. 2005a Factor VIII half-life and clinical phenotype of severe hemophilia A Haematologica 90 494 498
35. van Dijk K. Fischer K. van der Bom J.G. Grobbee D.E. van den Berg H.M. 2005b Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed Haemophilia 11 438 443
36. van Dijk K. Fischer K. van der Bom J.G. Scheibel E. Ingerslev J. van den Berg H.M. 2005c Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands British Journal of Haematology 130 107 112
37. Dimichele D. 2002 Inhibitors: resolving diagnostic and therapeutic dilemmas Haemophilia 8 280 287
38. Douglas S. 1999 Coagulation history, Oxford 1951-53 British Journal of Haematology 107 22 32
39. Ehrhardt A. Xu H. Dillow A.M. Bellinger D.A. Nichols T.C. Kay M.A. 2003 A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia Blood 102 2403 2411
40. Evatt B.L. Robillard L. 2000 Establishing haemophilia care in developing countries: using data to overcome the barrier of pessimism Haemophilia 6 131 134
41. Evatt B. Austin H. Leon G. Ruiz-Saez A. de Bosch N. 2000 Hemophilia treatment. Predicting the long-term risk of HIV exposure by cryoprecipitate Haemophilia 6 Suppl. 1 128 132
42. Evatt B.L. Black C. Batorova A. Street A. Srivastava A. 2004 Comprehensive care for haemophilia around the world Haemophilia 10 Suppl. 4 9 13
43. Farrugia A. Manno C.S. Evatt B.L. 2004 Emerging and receding risks of therapeutic regimens for haemophilia Haemophilia 10 Suppl. 4 47 54
44. Fiebig E.W. Busch M.P. 2004 Emerging infections in transfusion medicine Clinics in Laboratory Medicine 24 797 823 viii
45. Fischer K. Van den Berg H.M. Thomas R. Kumar S. Poonnoose P. Viswabandya A. Mathews V. Kavitha M.L. Bhattacharji S. Srivastava A. 2004 Dose and outcome of care in haemophilia - how do we define cost-effectiveness Haemophilia 10 Suppl. 4 216 220
46. Franchini M. 2004 Hepatitis C in haemophiliacs Thrombosis and Haemostasis 92 1259 1268
47. Giangrande P.L. 2004 Gene therapy for hemophilia? No Journal of Thrombosis and Haemostasis 2 1236 1237
48. Giangrande P.L. Mariani G. Black C. 2003 The WFH Haemophilia Centre Twinning Programme: 10 years of growth, 1993-2003 Haemophilia 9 240 244
49. Giles A.R. Rivard G.E. Teitel J. Walker I. 1998 Surveillance for factor VIII inhibitor development in the Canadian Hemophilia A population following the widespread introduction of recombinant factor VIII replacement therapy Transfusion Science 19 139 148
50. Gitschier J. Kogan S. Diamond C. Levinson B. 1991 Genetic basis of hemophilia A Thrombosis and Haemostasis 66 37 39
51. Goodeve A.C. Peake I.R. 2003 The molecular basis of hemophilia A: genotype-phenotype relationships and inhibitor development Seminars in Thrombosis and Hemostasis 29 23 30
52. Gordon F.H. Mistry P.K. Sabin C.A. Lee C.A. 1998 Outcome of orthotopic liver transplantation in patients with haemophilia Gut 42 744 749
53. Goudemand J. Rothschild C. Demiguel V. Vinciguerra C. Lambert T. Chambost H. Borel-Derlon A. Claeyssens S. Laurian Y. Calvez T. 2005 Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A Blood published online, DOI: 10.1182/blood-2005-04-1371
54. Gringeri A. 2003 Prospective controlled studies on prophylaxis Haemophilia 9 38 43
55. Hay C.R. 1998 Factor VIII inhibitors in mild and moderate-severity haemophilia A Haemophilia 4 558 563
56. Hay C.R.M. 2005 Inhibitors to FVIII/FIX:treatment of inhibitors-immune tolerance induction In: Textbook of Hemophilia ed. by Lee C.A. Berntorp E. Hoots K. pp 74 79 Blackwell Oxford q2
57. High K. 2005 Gene transfer for hemophilia: can therapeutic efficacy in large animals be safely translated to patients Journal of Thrombosis and Haemostasis 3 1682 1691
58. Hoots K. 2005 Transfusion-transmitted disease: history of epidemics (focus on HIV) In: Textbook of Hemophilia ed. by Lee C. Berntorp E. Hoots K. pp 200 206 Blackwells Oxford
59. Hunter N. Foster J. Chong A. McCutcheon S. Parnham D. Eaton S. MacKenzie C. Houston F. 2002 Transmission of prion diseases by blood transfusion Journal of General Virology 83 2897 2905
60. Ikkala E. Helske T. Myllyla G. Nevanlinna H.R. Pitkanen P. Rasi V. 1982 Changes in the life expectancy of patients with severe haemophilia A in Finland in 1930-79 British Journal of Haematology 52 7 12
61. Ironside J.W. Head M.W. 2004 Variant Creutzfeldt-Jakob disease: risk of transmission by blood and blood products Haemophilia 10 Suppl. 4 64 69
62. Journeycake J.M. Quinn C.T. Miller K.L. Zajac J.L. Buchanan G.R. 2001 Catheter-related deep venous thrombosis in children with hemophilia Blood 98 1727 1731
63. Keeney S. Mitchell M. Goodeve A. 2005 The molecular analysis of haemophilia A: a guideline from the UK haemophilia centre doctors' organization haemophilia genetics laboratory network Haemophilia 11 387 397
64. Kroner B.L. 1999 Comparison of the international immune tolerance registry and the North American immune tolerance registry Vox Sanguinis 77 Suppl. 1 33 37
65. Kulkarni R. Lusher J.M. 1999 Intracranial and extracranial hemorrhages in newborns with hemophilia: a review of the literature Journal of Pediatric Hematology/Oncology 21 289 295
66. Larsson S.A. 1985 Life expectancy of Swedish haemophiliacs, 1831-1980 British Journal of Haematology 59 593 602
67. Laub R. Di Giambattista M. Fondu P. Brackmann H.H. Lenk H. Saenko E.L. Felch M. Scandella D. 1999 Inhibitors in German hemophilia A patients treated with a double virus inactivated factor VIII concentrate bind to the C2 domain of FVIII light chain Thrombosis and Haemostasis 81 39 44
68. Lavery S. 2004 Preimplantation genetic diagnosis: new reproductive options for carriers of haemophilia Haemophilia 10 Suppl. 4 126 132
69. Lee C.A. Ironside J.W. Bell J.E. Giangrande P. Ludlam C. Esiri M.M. McLaughlin J.E. 1998 Retrospective neuropathological review of prion disease in UK haemophilic patients Thrombosis and Haemostasis 80 909 911
70. Levy J.H. Weisinger A. Ziomek C.A. Echelard Y. 2001 Recombinant antithrombin: production and role in cardiovascular disorder Seminars in Thrombosis and Hemostasis 27 405 416
71. Ljung R. 1999 Second Workshop of the European Paediatric Network for Haemophilia Management, 17-19 September 1998 in Vitznau/Switzerland Haemophilia 5 286 291
72. Ljung R.C. Sjorin E. 1999 Origin of mutation in sporadic cases of haemophilia A British Journal of Haematology 106 870 874
73. Ljung R. Aronis-Vournas S. Kurnik-Auberger K. van den Berg M. Chambost H. Claeyssens S. van Geet C. Glomstein A. Hann I. Hill F. Kobelt R. Kreuz W. Mancuso G. Muntean W. Petrini P. Rosado L. Scheibel E. Siimes M. Smith O. Tusell J. 2000 Treatment of children with haemophilia in Europe: a survey of 20 centres in 16 countries Haemophilia 6 619 624
74. Llewelyn C.A. Hewitt P.E. Knight R.S. Amar K. Cousens S. Mackenzie J. Will R.G. 2004 Possible transmission of variant Creutzfeldt-Jakob disease by blood transfusion Lancet 363 417 421
75. Lorenzo J.I. Lopez A. Altisent C. Aznar J.A. 2001 Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age British Journal of Haematology 113 600 603
76. Ludlam C.A. Mannucci P.M. Powderly W.G. 2005a Addressing current challenges in haemophilia care: consensus recommendations of a European Interdisciplinary Working Group Haemophilia 11 433 437
77. Ludlam C.A. Pasi K.J. Bolton-Maggs P. Collins P.W. Cumming A.M. Dolan G. Fryer A. Harrington C. Hill F.G. Peake I.R. Perry D.J. Skirton H. Smith M. 2005b A framework for genetic service provision for haemophilia and other inherited bleeding disorders Haemophilia 11 145 163
78. Lusher J.M. Lee C.A. Kessler C.M. Bedrosian C.L. 2003 The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A Haemophilia 9 38 49
79. von Mackensen S. Bullinger M. 2004 Development and testing of an instrument to assess the Quality of Life of Children with Haemophilia in Europe (Haemo-QoL) Haemophilia 10 Suppl. 1 17 25
80. Manco-Johnson M.J. Blanchette V.S. 2003 North American prophylaxis studies for persons with severe haemophilia: background, rationale and design Haemophilia 9 Suppl. 1 44 48 discussion 49
81. Mannucci P.M. 2003 AIDS, hepatitis and hemophilia in the 1980s: memoirs from an insider Journal of Thrombosis and Haemostasis 1 2065 2069
82. Mannucci P.M. 2005 Treatment of von Willebrand disease: desmopressin In: Textbook of Hemophilia ed. by Lee C.A. Berntorp E. Hoots K. pp 285 288 Blackwell Oxford
83. Messick K. Sanders J.C. Goedert J.J. Eyster M.E. 2001 Hepatitis C viral clearance and antibody reactivity patterns in persons with haemophilia and other congenital bleeding disorders Haemophilia 7 568 574
84. Mitchell M. Keeney S. Goodeve A. 2005 The molecular analysis of haemophilia B: a guideline from the UK haemophilia centre doctors' organization haemophilia genetics laboratory network Haemophilia 11 398 404
85. Montgomery R.R. Gill J.C. Scott J.P. 2003 Hemophilia and von Willebrand disease In: Nathan and Oski's Hematology of Infancy and Childhood Vol. 2 ed. by Nathan D.G. Orkin S.H. Ginsburg D. Look A.T. pp 1547 1576 W.B. Saunders Co. Philadelphia, PA
86. Morado M. Villar A. Jimenez Yuste V. Quintana M. Hernandez Navarro F. 2005 Prophylactic treatment effects on inhibitor risk: experience in one centre Haemophilia 11 79 83
87. Nathwani A.C. Davidoff A.M. Hanawa H. Hu Y. Hoffer F.A. Nikanorov A. Slaughter C. Ng C.Y. Zhou J. Lozier J.N. Mandrell T.D. Vanin E.F. Nienhuis A.W. 2002 Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques Blood 100 1662 1669
88. Negrier C. 2004 Gene therapy for hemophilia? Yes Journal of Thrombosis and Haemostasis 2 1234 1235
89. Nilsson I.M. Berntorp E. Lofqvist T. Pettersson H. 1992 Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B Journal of Internal Medicine 232 25 32
90. Oldenburg J. El-Maarri O. Schwaab R. 2002 Inhibitor development in correlation to factor VIII genotypes Haemophilia 8 Suppl. 2 23 29
91. Pavlovsky A. 1947 Contribution to the pathogeneisis of hemophilia Blood 2 185 191
92. Peden A.H. Head M.W. Ritchie D.L. Bell J.E. Ironside J.W. 2004 Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous patient Lancet 364 527 529
93. Peerlinck K. Arnout J. Di Giambattista M. Gilles J.G. Laub R. Jacquemin M. Saint-Remy J.M. Vermylen J. 1997 Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate Thrombosis and Haemostasis 77 80 86
94. Petrini P. 2001 What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B Haemophilia 7 99 102
95. Petrini P. Chambost H. Nemes L. 2004 Towards the goal of prophylaxis: experience and treatment strategies from Sweden, France and Hungary Haemophilia 10 Suppl. 4 94 96
96. Pipe S.W. 2005 The promise and challenges of bioengineered recombinant clotting factors Journal of Thrombosis and Haemostasis 3 1692 1701
97. Pollmann H. Richter H. Ringkamp H. Jurgens H. 1999 When are children diagnosed as having severe haemophilia and when do they start to bleed? A 10-year single-centre PUP study European Journal of Pediatrics 158 Suppl. 3 S166 S170
98. Pool J.G. Shannon A.E. 1965 Production of high-potency concentrates of antihemophilic globulin in a closed-bag system The New England Journal of Medicine 273 1443 1447
99. Poonnoose P.M. Manigandan C. Thomas R. Shyamkumar N.K. Kavitha M.L. Bhattacharji S. Srivastava A. 2005 Functional Independence Score in Haemophilia: a new performance-based instrument to measure disability Haemophilia 11 598 602
100. Ragni M. 2005 Transfusion-transmitted disease: hepatitis C virus infection and liver transplantation In: Textbook of Hemophilia ed. by Lee C.A. Berntorp E. Hoots K. pp 207 213 Blackwells Oxford
101. Rickard K.A. 1995 Guidelines for therapy and optimal dosages of coagulation factors for treatment of bleeding and surgery in haemophilia Haemophilia 1 8 13
102. Rizza C. 1981 Management of patients with inherited coagulation defects In: Haemostasis and Thrombosis ed. by Bloom A.L. Thomas D.P. pp 371 388 Churchill Livingstone Edinburgh
103. Rizza C.R. Spooner R.J. Giangrande P.L. 2001 Treatment of haemophilia in the United Kingdom 1981-1996 Haemophilia 7 349 359
104. Rosendaal F.R. Nieuwenhuis H.K. van den Berg H.M. Heijboer H. Mauser-Bunschoten E.P. van der Meer J. Smit C. Strengers P.F. Briet E. 1993 A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands. Dutch Hemophilia Study Group Blood 81 2180 2186
105. Rumi M.G. De Filippi F. Santagostino E. Colombo M. 2004 Hepatitis C in haemophilia: lights and shadows Haemophilia 10 Suppl. 4 211 215
106. Santagostino E. De Filippi F. Rumi M.G. Rivi M. Colombo M. Mannucci P.M. 2004 Sustained suppression of hepatitis C virus by high doses of interferon and ribavirin in adult hemophilic patients Transfusion 44 790 794
107. Scharrer I. Bray G.L. Neutzling O. 1999 Incidence of inhibitors in haemophilia A patients - a review of recent studies of recombinant and plasma-derived factor VIII concentrates Haemophilia 5 145 154
108. Schwartz R.S. Abildgaard C.F. Aledort L.M. Arkin S. Bloom A.L. Brackmann H.H. Brettler D.B. Fukui H. Hilgartner M.W. Inwood M.J. Kasper C.K. Kernoff P.B. Lusher J.M. Mannucci P.M. Scharrer I. MacKenzie M.A. Pancham N. Kuo H.S. Allred R.U. the Recombinant Factor VIII study group 1990 Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A. Recombinant Factor VIII Study Group New England Journal of Medicine 323 1800 1805
109. Sorensen B. Ingerslev J. 2005 Tailoring haemostatic treatment to patient requirements - an update on monitoring haemostatic response using thrombelastography Haemophilia 11 Suppl. 1 1 6
110. Soucie J.M. Nuss R. Evatt B. Abdelhak A. Cowan L. Hill H. Kolakoski M. Wilber N. 2000 Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators Blood 96 437 442
111. Soucie J.M. Symons J.t. Evatt B. Brettler D. Huszti H. Linden J. 2001 Home-based factor infusion therapy and hospitalization for bleeding complications among males with haemophilia Haemophilia 7 198 206
112. Srivastava A. 1999 Factor replacement for haemophilia - should cryoprecipitate be used Haemophilia 5 301 305
113. Srivastava A. 2004 Dose and response in haemophilia - optimization of factor replacement therapy British Journal of Haematology 127 12 25
114. Srivastava A. 2005a Optimizing clotting factor replacement therapy in hemophilia: a global need Hematology 10 Suppl. 1 229 230
115. Srivastava A. 2005b Gene therapy for hemophilia Journal of Thrombosis and Haemostasis 3 1313
116. Srivastava A. Chandy M. Sunderaj G.D. Lee V. Daniel A.J. Dennison D. Nair S.C. Mathews V. Anderson G. Nair A. Moses B.V. Sudarsanam A. 1998 Low-dose intermittent factor replacement for post-operative haemostasis in haemophilia Haemophilia 4 799 801
117. Stevenson A.C. Kerr C.B. 1967 On the distribution of frequencies of mutation to genes determining harmful traits in man Mutation Research 4 339 352
118. Stobart K. Iorio A. Wu J.K. 2005 Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B In: Cochrane Database Systamatic Review CD003429
119. Tenenbaum S.A. Morris C.A. Alexander S.S. McFerrin H.E. Garry R.F. Leissinger C.A. 2005 Evidence of HIV exposure and transient seroreactivity in archived HIV-negative severe hemophiliac sera Virology Journal 2 65
120. UK Ministry of Health 1968 Arrangements for the Care of Persons Suffering from Haemophilia and Related Disorders. Health memorandum HMSO London q3
121. Van Cott K.E. Monahan P.E. Nichols T.C. Velander W.H. 2004 Haemophilic factors produced by transgenic livestock: abundance that can enable alternative therapies worldwide Haemophilia 10 Suppl. 4 70 76
122. Wang L. Calcedo R. Nichols T.C. Bellinger D.A. Dillow A. Verma I.M. Wilson J.M. 2005 Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy Blood 105 3079 3086
123. Warrier I. 2005 Inhibitors in hemophilia B In: Textbook of Hemophilia ed. by Lee C. Berntorp E. Hoots K. pp 97 100 Blackwells Oxford
124. Warrier I. Lusher J.M. 1998 Development of anaphylactic shock in haemophilia B patients with inhibitors Blood Coagulation and Fibrinolysis 9 Suppl. 1 S125 S128
125. WFH 2000a Global Survey on Hemophilia WFH Montreal
126. WFH 2000b WFH Global Survey WFH Montreal
127. WFH 2005a Guidelines for the Management of Hemophilia ed. by WFH pp 1 47 WFH Montreal
128. WFH 2005b Benefits of treating hemophilia with factor concentrate In: Fact Sheets WFH Montreal q4
129. WFH 2005c World Federation of Hemophilia Annual Report 2004 WFH Montreal
130. WFH 2005d World Federation of Hemophilia Report on the Global Survey 2004 ed. by WFH WFH
131. White II. G.C. Roberts H.R. 2005 Gene therapy for hemophilia Journal of Thrombosis and Haemostasis 3 1312
132. Wight J. Paisley S. 2003 The epidemiology of inhibitors in haemophilia A: a systematic review Haemophilia 9 418 435
133. Wight J. Paisley S. Knight C. 2003 Immune tolerance induction in patients with haemophilia A with inhibitors: a systematic review Haemophilia 9 436 463
134. Xu L. Gao C. Sands M.S. Cai S.R. Nichols T.C. Bellinger D.A. Raymer R.A. McCorquodale S. Ponder K.P. 2003 Neonatal or hepatocyte growth factor-potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B Blood 101 3924 3932
135. Yee T.T. Williams M.D. Hill F.G. Lee C.A. Pasi K.J. 1997 Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a single intermediate purity factor VIII product Thrombosis and Haemostasis 78 1027 1029
136. Young N.L. Bradley C.S. Blanchette V. Wakefield C.D. Barnard D. Wu J.K. McCusker P.J. 2004 Development of a health-related quality of life measure for boys with haemophilia: the Canadian Haemophilia Outcomes-Kids Life Assessment Tool (CHO-KLAT) Haemophilia 10 Suppl. 1 34 43
137. Zhang J. Xu L. Haskins M.E. Parker Ponder K. 2004 Neonatal gene transfer with a retroviral vector results in tolerance to human factor IX in mice and dogs Blood 103 143 151